Study Results, Analyst Meetings, Upcoming Events, Financial Results, and Welfare Initiatives - Analyst Notes on Pharmacyclics, Thermo Fisher Scientific, Endo, Humana and Aetna

NEW YORK, May 19, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Pharmacyclics Inc. (NASDAQ: PCYC), Thermo Fisher Scientific, Inc. (NYSE: TMO), Endo International Plc (NASDAQ: ENDP), Humana Inc. (NYSE: HUM) and Aetna Inc. (NYSE: AET). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2609-100free.

--
Pharmacyclics  Inc.  Analyst  Notes
On May 14, 2014, Pharmacyclics Inc. (Pharmacyclics) announced that IMBRUVICA® (ibrutinib) will be highlighted in ten abstracts, including both company-sponsored research studies and investigator-sponsored studies. Pharmacyclics informed that the preliminary data from these abstracts about IMBRUVICA is currently accessible on the website of the American Society of Clinical Oncology (ASCO). However, the updated results will be presented at the 50th Annual Meeting of ASCO being held from May 30, 2014 through June 3, 2014, in Chicago, Illinois. Bob Duggan, CEO and Chairman of the Board, Pharmacyclics, commented, "Presentations at ASCO showcase IMBRUVICA's long-term efficacy and safety profile as a single agent, even in high-risk patients, as well as high response rates with long-term durability when IMBRUVICA is administered in combination with an antibody targeting CD20." The  full  analyst  notes  on  Pharmacyclics  are  available  to  download  free  of  charge  at:

http://www.analystsreview.com/2609-PCYC-19May2014.pdf

--
Thermo  Fisher  Scientific,  Inc.  Analyst  Notes
On May 5, 2014, Thermo Fisher Scientific, Inc. (Thermo Fisher Scientific) announced that the Company has scheduled its 2014 Analyst Meeting on May 20, 2014 from 9:00 a.m. to noon (EDT), at the New York Hilton Midtown, 1335 Avenue of Americas, New York City. The Company's senior management team will feature presentations at the meeting, including expectations for future financial performance. A live webcast of the presentation will be available for access on Thermo Fisher Scientific's website. The  full  analyst  notes  on  Thermo  Fisher  Scientific  are  available  to  download  free  of  charge  at:

http://www.analystsreview.com/2609-TMO-19May2014.pdf

--
Endo  International  Plc  Analyst  Notes
On May 9, 2014, Endo International Plc (Endo) announced that Rajiv De Silva, President and CEO of the Company will present a corporate overview at the UBS Global Healthcare Conference to be held on May 21, 2014 at 9:00 a.m. ET. The Company informed that a webcast of the conference will be accessible at Endo's website. The  full  analyst  notes  on  Endo  are  available  to  download  free  of  charge  at:

http://www.analystsreview.com/2609-ENDP-19May2014.pdf

--
Humana  Inc.  Analyst  Notes
On May 7, 2014, Humana Inc. (Humana) reported Q1 2014 earnings. Humana posted an increase of 11.7% YoY in total revenues to $11.7 billion, with an increase of 11.8% YoY in total premiums and services revenue. According to the Company, increase in premiums and services revenue was primarily driven by higher Retail and Employer Group segment revenues resulting from higher average individual and group Medicare membership and higher individual commercial membership, partially offset by the impact of sequestration. Net income declined to $368 million, or $2.35 per diluted share, from $473 million, or $2.95 per diluted share, in Q1 2013. Analysts polled by Thomson Reuters expected the Company to report earnings of $1.94 per share for Q1 2014. The Company reaffirmed its EPS estimate for full-year 2014 in the range of $7.25 and $7.75. On the same day, the shares of Humana rallied 8.43% to end the day at $119.05. The  full  analyst  notes  on  Humana  are  available  to  download  free  of  charge  at:

http://www.analystsreview.com/2609-HUM-19May2014.pdf

--
Aetna  Inc.  Analyst  Notes
On May 6, 2014, Aetna Inc. (Aetna), together with the National Kidney Foundation and Welltok launched a pilot project, which aims to help Aetna members suffering from Chronic Kidney Disease (CKD) connect with peers and learn to cope with their condition. Aetna Innovation Labs seeks to identify members with CKD for Welltok's CaféWell Chronic Kidney Disease Community. The Company informed that these members will be invited to join the online community, where they can interact with "peer/patient" mentors who also have CKD and have been trained by the National Kidney Foundation. With the help of interaction at online community, participants will also learn more about managing their kidney disease, diet and nutrition, treatment options and living well. Michael Palmer, Vice President, Chief Innovation and Digital Officer at Aetna, commented "Early intervention and social support also may help provide better long-term clinical results and a higher quality of life." The  full  analyst  notes  on  Aetna  are  available  to  download  free  of  charge  at:

http://www.analystsreview.com/2609-AET-19May2014.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review